I am a
Home I AM A Search Login

Papers of the Week

Papers: 31 Dec 2022 - 6 Jan 2023

2022 Dec 28

Expert Opin Drug Saf

A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.


Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, Sakurai F, Ning X, Nakai M, Koga N
Expert Opin Drug Saf. 2022 Dec 28:1-8.
PMID: 36578197.


Fremanezumab is a humanized monoclonal antibody against calcitonin gene-related peptide for subcutaneous use to suppress migraine attacks. A phase 3 study was conducted to investigate the safety of autoinjector (AI)-assisted self-injection of fremanezumab 225 mg.